GenSpera goes public

The announcement comes nearly two months after GenSpera, a developmental stage cancer drug company, received approval from the Food and Drug Administration to begin a Phase I clinical trial of its lead drug, G-202.

“The quotation of our common stock on the OTCBB is another important milestone in the growth of our company, especially as it follows FDA approval to start our first clinical trial, which we plan to commence later this year,” CEO Dr. Craig Dionne said in a statement. “We hope this will increase GenSpera’s exposure to the investment community and we are excited to enter this new phase of our company evolution.”